Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanoparticle Breast Cancer Drug O.K.D by FDA

Abstract:
"The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel."

Nanoparticle Breast Cancer Drug O.K.D by Food and Drug Administration

March 10, 2005

Research at Northwestern University Feinberg School of Medicine played a significant role in Food and Drug Administration approval of AbraxaneTM (paclitaxel protein-bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.

“The approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel,” said principal clinical study investigator William J. Gradishar, M.D., associate professor of medicine, division of hematology/oncology at Feinberg and co-director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital.

Gradishar is also a breast cancer researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

“In our research, participants who no longer responded to some of the more common treatments showed improvement with Abraxane and experienced less-severe side effects that made treatment more tolerable,” Gradishar said.

Abraxane is engineered using a proprietary process (protein-bound nanoparticle technology) to create tiny particles (nanoparticles 100th the size of a red blood cell) in which the active chemotherapeutic drug, paclitaxel, is bound to a naturally occurring protein called albumin.

By using this nanotechnology, the active component (paclitaxel) can be delivered into the body at a 50 percent higher dose over 30 minutes.

This contrasts with Taxol, in which paclitaxel is dissolved in a toxic solvent, which requires pre-medication with steroids and antihistamines to avoid hypersensitivity reactions and must be given in infusions for up to three hours.

Because Abraxane is solvent-free, solvent-related toxicities are eliminated and premedication is not required.

In the clinical studies, the response rate for all participants treated with Abraxane was almost twice that of participants receiving the solvent-based paclitaxel injection. Without toxic solvents, Abraxane could be given at higher doses than Taxol, which may account, in part, for the increased anti-tumor activity.

In addition, albumin is a protein that normally transports nutrients to cells and has been shown to accumulate in rapidly growing tumors. Therefore, Abraxane’s increased effectiveness may also be due to preferential delivery of albumin-bound paclitaxel to cancer cells.

Abraxane was developed by American Bioscience and will be marketed by Abraxis Oncology, a division of American Pharmaceutical Partners.



Media Contact:
Elizabeth Crown
312-503-8928
e-crown@northwestern.edu

Copyright © Northwestern University

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

JPK talks with Dr Frank Lafont, Director of the BioImaging Center Lille (BICeL) about the use of the NanoWizard® AFM together with fluorescence microscopy in the study of living cells June 19th, 2018

Powering the 21st Century with Integrated Photonics: UCSB-Led Team Selected for Demonstration of a Novel Waveguide Platform Which is Transparent Throughout the MWIR and LWIR Spectral Bands June 19th, 2018

Executives Explore Key Megatrends and Innovations in MEMS, Sensors, Imaging Tech at SEMI-MSIG European Summits: Speakers to share developments in smart automotive, smart cities, smart industrial, biomedical, consumer and IoT, September 19-21, 2018 in Grenoble, France June 19th, 2018

Carbon nanotube optics poised to provide pathway to optical-based quantum cryptography and quantum computing: Researchers are exploring enhanced potential of carbon nanotubes for unique applications June 18th, 2018

Nanomedicine

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

JPK talks with Dr Frank Lafont, Director of the BioImaging Center Lille (BICeL) about the use of the NanoWizard® AFM together with fluorescence microscopy in the study of living cells June 19th, 2018

Camouflaged nanoparticles used to deliver killer protein to cancer June 17th, 2018

Graphene carpets: So neurons communicate better: Research by SISSA reveals that graphene can strengthen neuronal activity, confirming the unique properties of this nanomaterial. The study has been published on Nature Nanotechnology June 13th, 2018

Announcements

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

JPK talks with Dr Frank Lafont, Director of the BioImaging Center Lille (BICeL) about the use of the NanoWizard® AFM together with fluorescence microscopy in the study of living cells June 19th, 2018

Powering the 21st Century with Integrated Photonics: UCSB-Led Team Selected for Demonstration of a Novel Waveguide Platform Which is Transparent Throughout the MWIR and LWIR Spectral Bands June 19th, 2018

Executives Explore Key Megatrends and Innovations in MEMS, Sensors, Imaging Tech at SEMI-MSIG European Summits: Speakers to share developments in smart automotive, smart cities, smart industrial, biomedical, consumer and IoT, September 19-21, 2018 in Grenoble, France June 19th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project